Plain-English translation of NCT07178093 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This study doesn't follow the usual testing phases — it may be an observational study or a different type of research.
This trial is testing whether Antrodia cinnamomea, a medicinal fungus used traditionally in Taiwan, can help patients feel better after undergoing a procedure called transcatheter hepatic artery chemoembolization (TACE) — a treatment that delivers cancer-fighting drugs directly to liver tumors. Some patients experience side effects like fever, nausea, belly pain, and liver function problems after this procedure. Researchers want to know if this medication can reduce these side effects and help the liver recover faster.
After TACE, many patients suffer from uncomfortable side effects and temporary liver damage. There is currently no standard treatment to prevent or ease these problems. This medication has been used in Taiwan for years and shows promise in protecting the liver and fighting tumors, so researchers want to test whether it can make TACE safer and more tolerable for patients.
You likely qualify if…
You likely don't qualify if…
You would receive the standard TACE procedure for your liver cancer, and then be randomly assigned to take either the medicinal fungus supplement or a placebo. You would start taking capsules 3 days before your procedure and continue for 7 days after — taking 2 capsules twice daily with meals for a total of 11 days. The study team will monitor your liver function, symptoms like nausea and fever, quality of life, and hospital stay to see if the medication helps you recover better than the placebo group.
AI-generated summary from trial data · Jun 4, 2026 · Not medical advice
Taiwan
Sponsor
Taichung Tzu Chi Hospital
Enrollment target
~60 participants
Started
January 2023
Primary completion
December 2025
This trial's estimated completion date has passed — the record may not be fully up to date.
Age range
20 Years – 80 Years
Last updated on clinicaltrials.gov in September 2025.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Yu Cheng-Chan, Dr
Taichung Tzu Chi Hospital
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.